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PXPEDITED REVIEWS
ate Clinical Events After
lopidogrel Discontinuation May
imit the Benefit of Drug-Eluting Stents
n Observational Study of Drug-Eluting Versus Bare-Metal Stents
atthias Pfisterer, MD, FACC,* Hans Peter Brunner-La Rocca, MD,* Peter T. Buser, MD, FACC,*
eter Rickenbacher, MD,§ Patrick Hunziker, MD,† Christian Mueller, MD,‡ Raban Jeger, MD,*
ranziska Bader, RN,* Stefan Osswald, MD, FACC,* Christoph Kaiser, MD,* for the
ASKET-LATE Investigators
asel, Switzerland
OBJECTIVES We sought to define the incidence of late clinical events and late stent thrombosis in patients
treated with drug-eluting (DES) versus bare-metal stents (BMS) after the discontinuation of
clopidogrel as well as their timing and outcome.
BACKGROUND There is growing concern that delayed endothelialization after DES implantation may lead to
late stent thrombosis and related myocardial infarction (MI) or death. However, event rates
and outcomes after clopidogrel discontinuation versus BMS are unknown.
METHODS A consecutive series of 746 nonselected patients with 1,133 stented lesions surviving 6
months without major events were followed for 1 year after the discontinuation of
clopidogrel. Patients were assigned randomly 2:1 to DES versus BMS in BASKET (Basel
Stent Kosten Effektivitäts Trial). The primary focus of this observation was cardiac death/MI.
RESULTS Rates of 18-month cardiac death/MI were not different between DES and BMS patients.
However, after the discontinuation of clopidogrel (between months 7 and 18), these events
occurred in 4.9% after DES versus 1.3% after BMS implantation. Target vessel revascular-
ization remained lower after DES, resulting in similar rates of all clinical events for this time
period (DES 9.3%, BMS 7.9%). Documented late stent thrombosis and related death/target
vessel MI were twice as frequent after DES versus BMS (2.6% vs. 1.3%). Thrombosis-related
events occurred between 15 and 362 days after the discontinuation of clopidogrel, presenting
as MI or death in 88%.
CONCLUSIONS After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel
revascularization is maintained but has to be balanced against an increase in late cardiac death
or nonfatal MI, possibly related to late stent thrombosis. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.0262584–91) © 2006 by the American College of Cardiology Foundation
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erug-eluting stents (DES) are more effective than bare-
etal stents (BMS) in reducing restenosis and related target
essel revascularization (TVR) (1–6), mainly by limiting
ntimal hyperplasia (7), with similar rates in death or
onfatal myocardial infarction (MI). However, concern is
See page 2592
rowing that delayed endothelialization, incomplete neoin-
imal healing, or hypersensitivity reactions after the implan-
ation of DES may lead to MI and death as the result of late
tent thrombosis (8). The U.S. Food and Drug Adminis-
ration even issued a warning in this regard (9). Although
From the *Departments of Cardiology, †Intensive Care Medicine, and ‡Internal
edicine, University Hospital and §Bruderholzspital, Basel, Switzerland. This study
as supported by the Basel Cardiac Research Foundation, Basel, Switzerland, and the
niversity Hospital, Basel, Switzerland. They had no role in the design and conduct
f the study, collection, management, analysis, or interpretation of the data. There
as no industry sponsor for this study.(
Manuscript received June 6, 2006; revised manuscript received August 24, 2006,
ccepted August 28, 2006.he incidence of subacute stent thrombosis was 1.0% to
.5% within the first 30 days after stenting and 0.5%
etween 1 and 6 months without significant differences
etween patients treated with DES and BMS in random-
zed trials (10–13), there are only limited data on later
vents (13–15). One major reason for late stent thrombosis
ay be the reduction of dual antiplatelet therapy (15–17),
hich currently is recommended for 1 month after BMS,
or 3 months after sirolimus-eluting stents, and for 6
onths after paclitaxel-eluting stents (18). However, there
emains widespread uncertainty regarding the risk of clinical
vents after the discontinuation of clopidogrel, particularly
fter DES implantation.
To address these questions, we prospectively followed a
onsecutive series of 746 nonselected patients randomized
o DES versus BMS who survived the first 6 months after
tenting without major clinical events and who stopped
aking clopidogrel at that point in time. They initially were
nrolled in the Basel stent cost-effectiveness trial, BASKET
Basel Stent Kosten-Effektivitäts Trial) (19). The specific
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December 19, 2006:2584–91 Late Clinical Events After DES Versus BMSims of this prospective follow-up evaluation were to define
he incidence of late clinical events and late stent thrombosis
n DES- versus BMS-treated patients after the discontinu-
tion of clopidogrel and to define predictors, timing, and
utcome of such thrombotic events in relation to stent type
mplanted.
ETHODS
atient population and study design. Of a consecutive
eries of 988 patients treated with percutaneous coronary
ntervention and stenting between May 5, 2003, and May
1, 2004, at the University Hospital of Basel, Switzerland,
62 (16%) had to be excluded for a target vessel diameter of
mm or greater (largest DES size available 3.5 mm; n 
3), for presence of restenotic lesions (n  49), and for no
onsent (mostly because of patient or referring physician
reference for DES; n 90), leaving 826 patients who were
nrolled in BASKET (19). They were assigned randomly in
2:1 fashion to DES versus BMS (i.e., 545 patients received
ES) (Cypher Cordis, Johnson & Johnson, Miami Lakes,
lorida, n  264 or Taxus, Boston Scientific Corporation,
atick, Massachussetts, n  281) and 281 patients a
hird-generation cobalt-chromium BMS (Vision, Guidant
orp., Indianapolis, Indiana) and were followed for death,
onfatal MI, and TVR. Target vessel revascularization was
clinical event because control angiography was not allowed
ithout symptoms or signs of ischemia in this study. All 746
atients with a total of 1,133 stented lesions who survived
he first 6 months without nonfatal MI or repeat TVR were
nrolled in the present BASKET-LATE (BASKET LAte
hrombotic Events) study and followed for another 12
onths (Fig. 1). Patients originated from the University
ospital of Basel and 4 affiliated hospitals without their
wn catheterization laboratory (see Appendix). This study
as approved by the Ethics Committee of Basel, and each
atient gave written informed consent.
ollow-up. After 18 months, all patients received a ques-
ionnaire with specific questions regarding rehospitaliza-
ions, adverse events, and drug therapy. Data of patients
ith repeat procedures were collected prospectively. Addi-
ional data were obtained from primary care physicians,
Abbreviations and Acronyms
BASKET  Basel Stent Kosten Effektivitäts
Trial
BASKET-LATE  BASKET LAte Thrombotic Events
Trial
BMS  bare-metal stent
CI  confidence interval
DES  drug-eluting stent
HR  hazard ratio
MI  myocardial infarction
OR  odds ratio
TVR  target vessel revascularizationeferring cardiologists, patients, or relatives when necessary. cen patients were alive and well but did not consent to
ollow-up questioning (they are included in survival analy-
es), whereas 3 had moved out of the country and could not
e located. Thus, follow-up was complete in 743 of the 746
atients (99.6%) regarding survival and in 733 (98.3%)
egarding all events (Fig. 1).
ngioplasty and antiplatelet therapy. Angioplasty was
erformed according to standard techniques with the final
ecision about the appropriate strategy in each patient left
o the judgment of the physician in charge (19). All 157
atients presenting with ST-segment elevation MI were
reated with primary angioplasty and all 273 patients with
ther acute coronary syndromes with urgent agioplasty
ithin 24 h of presentation. All patients received a loading
ose of 250 to 500 mg aspirin intravenously or orally and
lopidogrel 300 mg orally. The use of glycoprotein IIb/IIIa
nhibitors was left to the discretion of the physician in
harge, mainly given in patients with acute coronary syn-
romes, complex lesions, or suboptimal angioplasty results.
ll patients received a maintenance dual antiplatelet therapy
ith aspirin 100 mg and clopidogrel 75 mg daily for 6
onths, irrespective of stent type used. In addition, in all
atients long-term statin therapy was prescribed. Patients
ere advised to stop clopidogrel after 6 months but to
ontinue 100 mg of aspirin daily long-term. Medication was
ecorded at follow-up and at the time of any event.
efinition of late events. For this study, “late“ was defined
s occurring between 7 and 18 months after stenting. Late
igure 1. Patient flow chart. Note that 746 of 826 patients (90.3%)
urviving the initial 6 months without major cardiac events were enrolled.
ollow-up regarding survival was complete in 743 of 746 patients (99.6%),
hereas 10 patients were alive and well but did not consent to detailed
nformation. BMS  bare-metal stent; DES  drug-eluting stent.linical events, the focus of this observation, were any
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Late Clinical Events After DES Versus BMS December 19, 2006:2584–91ardiac death and documented nonfatal MI. Of these
vents, all sudden cardiac deaths and all MIs attributable to
he target vessel were considered to be “thrombosis-related”
previously called “possible” thromboses) (11). Angio-
raphically documented “definite” late stent thrombosis was
efined as ischemic clinical event with angiographically
roven stent thrombosis (i.e., Thrombosis In Myocardial
nfarction [TIMI] flow 0 or 1 or the presence of flow-
imiting thrombus [TIMI flow 1 or 2]). Target vessel
evascularizations not related to thrombosis-related events
ere assumed to be “restenosis-related.” Thus, major car-
iac events were a composite of cardiac death, nonfatal MI,
nd TVR. All deaths not clearly due to other causes like
ancer or suicide were considered to be cardiac. Nonfatal
I was diagnosed according to current guidelines (20). All
hese events were adjudicated by an independent clinical
vent committee blinded to the stent types used.
tatistics. All analyses were performed with the primary
im to compare patients with DES and BMS and to
erform additional secondary exploratory analyses between
he 2 DES used. Because this study was planned as
ollow-up investigation of BASKET, sample size calcula-
ions were performed for that purpose (19). Therefore,
atients were followed in an “observational” manner, which
id not allow formal statistical comparisons for the time
eriod of month 7 to 18. Quantitative variables are pre-
ented as mean  standard deviation or median  inter-
uartile ranges as appropriate. Categorical variables are
escribed by their distribution. Two-group comparisons
ere performed using the Fisher exact test for categorical
ariables and unpaired t test or Mann-Whitney U test for
uantitative variables. Kaplan-Meier curves were used for
alculating time-dependent occurrences of events and the
og rank test to compare DES and BMS. Predictors with a
value 0.1 were entered in a multivariate Cox-regression
nalysis adjusted to differences in baseline characteristics to
est independence of these predictors. All calculations were
erformed with the use of a commercially available statisti-
al package (version 13.0, SPSS Inc., Chicago, Illinois).
ESULTS
aseline characteristics. Baseline characteristics of all 826
atients included in BASKET have been described previ-
usly (19). The baseline characteristics of patients surviving
he first 6 months without major cardiac events did not
iffer between patients treated with DES and BMS apart
rom the total stent length and the use of small stents 2.5
m (Table 1). This was true despite the fact that fewer
atients treated with DES had such events during the first
months compared with patients treated with BMS (7.2%
s. 12.1%, p  0.02) (19). Baseline characteristics reflect a
elatively high-risk patient population presenting often with
cute coronary syndromes and an extensive, complex coro-
ary anatomy as seen in contemporary high-volume centers. oate clinical events. After the discontinuation of clopi-
ogrel, the rate of cardiac death or nonfatal MI between
onths 7 and 18 was low; however, all 6 cardiac deaths and
0 of 23 MIs (87%) occurred in patients who had received
ES, resulting in a higher rate of cardiac death and nonfatal
I for DES compared with BMS-treated patients (Fig. 2).
n contrast, the rate of restenosis-related TVR tended to be
ower in DES patients, resulting in a comparable rate of
ajor cardiac events for this time period (9.3% vs. 7.9%,
ES vs. BMS, respectively).
To compare long-term effects, cumulative event rates
ere calculated during the whole follow-up period and apart
rom intervention-related early events (initial 30 days).
ecause the rate of procedure-related 30-day death and
onfatal MI were greater after BMS compared with DES
4.6% vs. 2.0%, p  0.05, rather because of patient charac-
eristics [acute MI patients]/chance than to stent type used
21] and certainly not to drug-effects of DES), the overall
ate of cardiac death/nonfatal MI was not different between
ES and BMS use for the entire 18-month period (8.4% vs.
.5%, p  0.63), but the rate of TVR remained lower (7.5%
s. 11.6%, p  0.04) (Figs. 3A and 3B). Focusing on late
vents and excluding the early intervention-related hazard,
ates of death and nonfatal MI were similar in both groups up
o 6 months. However, although the curve flattened later on in
atients receiving BMS, there was a constant increase during
he entire period in these events after DES implantation (Fig.
C). In multivariate analysis, DES was accompanied with a
ignificantly increased risk for these events (hazard ratio [HR]
.2, 95% confidence interval [CI] 1.1 to 4.7, p  0.03). In
ontrast, the benefit of DES over BMS was maintained
ong-term for restenosis-related TVR (Fig. 3D). In multivar-
ate analysis, DES nearly halved the risk of restenosis-related
VR (HR 0.52, 95% CI 0.33 to 0.85, p  0.009).
Exploratory subanalyses showed that there were no sig-
ificant differences between the 2 DES used in any of these
nalyses; however, this was not expected based on low event
ates and sample sizes of these subgroups (18 months
ardiac death/MI for Cypher, 7.2%; Taxus, 9.6%; p 0.31).
ate thrombosis-related events. After the discontinuation
f clopidogrel, 16 of 65 events (25%) were related to stent
hrombosis: 3 cardiac deaths, 11 nonfatal MIs, and 2
ngiographically proven subtotal thrombotic obstructions
ith increasing angina but no infarction. Late stent throm-
osis was documented in one patient who died (the other 2
atients died suddenly without autopsy) and in 8 of 11
atients with MI. Figure 4 shows the incidence of these late
hrombosis-related events in relation to the stent type
mplanted. Although differences were not significant in view
f the relatively low overall frequencies, there was a 2- to
-fold increased rate of such late events in DES- compared
ith BMS-treated patients. Importantly, however, these
ndings between DES versus BMS were consistent and
ongruent with the primary focus of this study.
Thrombosis-related events occurred after a median timef 116 (interquartile range 53 to 313) days after the
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December 19, 2006:2584–91 Late Clinical Events After DES Versus BMSiscontinuation of clopidogrel, with a wide range between
5 and 362 days (Fig. 5). Seven patients presented between
onths 7 and 9, 3 between months 10 and 12, and the
emaining 5 between months 13 and 18. One event oc-
urred on continued dual antiplatelet therapy (patient after
revious coronary surgery and implantable cardioverter-
efibrillator implantation for severe 3-vessel disease) and
ne 28 days after stopping aspirin as well.
redictors of late thrombosis-related events. Patients
ith late thrombosis-related events after the discontinua-
ion of clopidogrel differed at baseline from those without
uch events in that they had more previous MIs (56% vs.
7%, odds ratio [OR] 3.5, p  0.01), an increased need for
lycoprotein IIb/IIIa inhibitors (56% vs. 25%, OR 3.9, p 
.006), more side branch occlusions (9% vs. 3%, OR 4.0, p
0.05), and bypass graft stenting (25% vs. 5%, OR 6.3, p
0.0001). Note that this analysis was performed in patients
nly after the discontinuation of clopidogrel (i.e., surviving
he first 6 months without major adverse cardiac events),
Table 1. Baseline Characteristics
Age, yrs
Male, n (%)
History, n (%)
Diabetes
Hypertension
Hypercholesterolemia
Current smoking
Previous MI
Previous PCI
Previous CABG
Presentation, n (%)
STEMI
Unstable
Stable
Coronary angiogram, n (%)
Multivessel disease
LAD
LCX
RCA
Left main
Bypass graft
Baseline intervention
Number of lesions
Glycoprotein IIb/IIIa blockers, n (%)
Stented segments per patient, n
1 segments per patient, n (%)
1 segments 2.5 mm, n (%)
Stents per segment, n
Implanted stents per patient, n
Stents 2.5 mm, n (%)*
Bifurcation lesions treated, n (%)
CTO treated, n (%)
Total stent length per patient, mm*
Lesions with angiographic success, n (%)
*p  0.05 BMS vs. DES.
BMS  bare metal stent; CABG  coronary artery bypa
stent; LAD  left anterior descending; LCX  left circum
intervention; RCA  right coronary artery; STEMI  ST-hich may implicate a certain selection bias. eutcome of late thrombosis-related events. Comparing
resentation and outcome of the 16 thrombosis-related with
he 49 other events during months 7 to 18 showed that in
hrombosis-related events, cardiac mortality was somewhat
igher (19% vs. 6%, p  0.13) and the rate of nonfatal MIs
ignificantly higher (75% vs. 22%, p  0.0001). Thus,
hrombosis-related events carried a substantially increased
isk of cardiac death or nonfatal MI compared with non-
hrombosis–related events (88% vs. 27%, OR 19.4, p 
.0001).
ISCUSSION
his prospective randomized comparison of DES versus
MS in a “real-world” setting shows for the first time that
he incidence of late cardiac death or nonfatal MI after the
iscontinuation of clopidogrel is greater in DES- as com-
ared with BMS-treated patients. Most of this difference
as attributed to an increased rate of thrombosis-related
erall
743)
DES
(n  499)
BMS
(n  244)
 11.3 63.6  11.3 63.5  10.8
(78.6) 393 (78.8) 181 (78.3)
(18.3) 84 (16.9) 51 (21.1)
(66.5) 327 (66.1) 164 (67.5)
(77.3) 383 (77.2) 186 (77.5)
(28.3) 133 (26.8) 76 (31.4)
(27.3) 137 (27.5) 66 (27.0)
(16.1) 83 (16.6) 35 (14.3)
(12.4) 66 (13.2) 26 (10.7)
(21.1) 105 (21.0) 52 (21.3)
(36.7) 183 (36.7) 90 (36.9)
(42.3) 211 (42.3) 102 (41.8)
(66.8) 332 (66.5) 164 (67.2)
(51.4) 260 (52.1) 122 (50.0)
(31.0) 154 (30.9) 76 (31.1)
(35.1) 177 (35.5) 84 (34.4)
(1.1) 3 (0.6) 5 (2.0)
(5.4) 31 (6.2) 9 (3.7)
,133 767 366
(25.7) 128 (25.7) 61 (25.0)
 0.7 1.5  0.7 1.4  0.6
(41.3) 214 (42.9) 93 (38.1)
(26.8) 145 (29.1) 54 (22.1)
 0.5 1.3  0.5 1.3  0.5
 1.0 1.9  1.1 1.8  1.0
(26.8) 145 (29.1) 54 (22.1)
(5.1) 23 (4.6) 15 (6.1)
(3.5) 13 (2.6) 13 (5.3)
 20 34  21 31  19
(95.8) 480 (96.2) 232 (95.1)
ting; CTO  chronic total occlusions; DES  drug-eluting
I  myocardial infarction; PCI  percutaneous coronary
nt elevation myocardial infarction.Ov
(n 
63.6
584
135
491
569
209
203
118
92
157
273
313
496
382
230
261
8
40
1
189
1.5
307
199
1.3
1.9
199
38
26
33
712
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Late Clinical Events After DES Versus BMS December 19, 2006:2584–91onfatal MI than non-thrombosis–related events and oc-
urred anytime between 15 and 362 days after the discon-
inuation of clopidogrel. Patients with a history of MI, the
eed for glycoprotein IIb/IIIa inhibitors at baseline, side-
ranch occlusions, or bypass graft stenting seemed to be at
ncreased risk for such events. In contrast, there was a
ontinued benefit of DES in reducing restenosis-related
VRs. These observational data suggest, therefore, that late
linical events possibly related to late stent thrombosis after
he discontinuation of clopidogrel may limit the net clinical
enefit of DES.
ate thrombotic stent occlusion. Late and sudden throm-
otic coronary occlusion after percutaneous coronary inter-
igure 2. Late major cardiac events (months 7 to 18). Note that the primar
as significantly greater in drug-eluting stent (red) versus bare-metal sten
arget vessel revascularization (TVR) rate after drug-eluting stents.
igure 3. Cardiac death/myocardial infarction (MI) and restenosis-related t
tent (BMS) implantation. Comparison of the occurrence of cardiac dea
evascularization (TVR, B and D) after DES (red) versus BMS (blue) implanta
o drug-eluting properties of the stents are included (A and B, period 0 to 18entions was first noted as a significant problem 2 to 15
onths after brachytherapy (22). In contrast, meta-analyses
f initial long-term outcomes after sirolimus-eluting (10,23)
r paclitaxel-eluting stent implantation (12) pointed to the
verall benefit of DES compared with BMS in selected
atient groups and suggested no increased hazard of stent
hrombosis compared with BMS use. However, there were
ase reports (8,16) demonstrating the occurrence of late
tent thrombosis after DES implantation associated with a
igh risk of death or nonfatal MI. Reasons for thrombotic
vents were described in experimental (24) and autopsy
tudies (25): DES may delay endothelialization and impair
ntimal healing, partly in association with hypersensitivity
s of this observation, cardiac death or nonfatal myocardial infarction (MI),
e) groups, which contrasts with a trend toward a lower restenosis-related
vessel revascularization (TVR) after drug-eluting (DES) versus bare-metal
nfatal MI (A and C) and the need for “restenosis-related” target vessely focuarget
th/notion. Note that in this graph, the initial 30-day events that are not related
months) or disregarded (C and D, period 1 to 18 months).
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December 19, 2006:2584–91 Late Clinical Events After DES Versus BMSnd inflammatory reactions, and thereby extend the time
indow during which stents are prone to thrombosis (8).
his has been confirmed recently by angioscopic findings
26). Two large cohort-studies on 2,000 patients each
nalyzed their data for late angiographic stent thrombosis
fter DES implantation and reported an incidence of up to
.7% during a follow-up duration of 9 and 18 months,
espectively (13,15). Events occurred between 2 and 26
onths, with case fatality rates of 29% and 45%. In the
resent report, rates of late angiographically documented
tent thrombosis and thrombosis-related clinical events
ere even greater (1.6% and 2.6%, respectively). However,
ASKET-LATE differs from previous such trials: late
ollow-up data were collected prospectively, more complex
esions were treated, almost 60% patients had acute coronary
yndromes (one-third of them with ST-segment elevation
yocardial infarction, 26% treated acutely with glycoprotein
Ib/IIIa inhibitors), and clopidogrel was discontinued in all
atients after 6 months with no protocol-driven control
ngiograms allowed and therefore no angiogram-driven
igure 4. Late stent thrombosis and related clinical events. Late angio-
raphically documented stent thrombosis and thrombosis-related clinical
vents for drug-eluting (red) versus bare-metal (blue) stent-treated pa-
ients. Note the overall low rates with formally nonsignificant differences
ut consistent findings of these events.Figure 5. Timing of late thrombotic events after clopidogrel discontepeat TVRs performed. In fact, several of these high-risk
haracteristics of the BASKET population turned out to be
redictors of late thrombosis-related events, among them
tenting of bifurcation or bypass-graft lesions. In contrast,
he rate of clinically driven late restenosis-related TVRs
emained lower after DES versus BMS. Of clinical rele-
ance for the patient, however, is the “price” to pay (i.e., the
igh rate of cardiac deaths or nonfatal MI associated with
ate thrombosis-related events).
mplications of BASKET-LATE findings. The findings
f BASKET-LATE may have major clinical implications.
irst, when using an antiplatelet regime as currently recom-
ended and applied in BASKET/BASKET-LATE, one
as to balance the benefit of the lower rate of reinterventions
fter DES implantation with the cost of an increased rate of
ate, presumably thrombosis-related, death or nonfatal MI
ompared with BMS use. In nonselected patients, implan-
ation of DES may avoid 5 major cardiac events at 6 months
n 100 patients treated (19) but lead to 3 patients suffering
ardiac death or nonfatal MI during months 7 to 18.
econd, one may speculate whether prolonged dual anti-
latelet therapy may be beneficial as suggested after brachy-
herapy (27) and BMS implantation (28). However, the
ide time window in which these thrombotic events occur,
s noted in this study and in registry data by Ong et al. (15),
ay question a direct relation of clopidogrel discontinuation
ith these events, although clopidogrel withdrawal may
ven be associated with proinflammatory and prothrombotic
ffects in diabetic patients (29). In addition, the bleeding
isk of prolonged dual antiplatelet therapy of up to 2% per
ear (30,31) and the increased cost would have to be taken
nto account. Therefore, such a prolonged dual antiplatelet
herapy may only be justified in patients at increased risk for
uch events (13,15,32). Third, new strategies to reduce late
hrombosis-related events have to be searched for; they may
onsist of other antiplatelet regimes, other stent types (e.g.,
ioabsorbable or endothelialization promoting stents) (33)
r other drugs/drug dosages or drug release kinetics of DES.
t may also be important to identify individual patient
actors such as aspirin (34) or clopidogrel resistance (35), orinuation. Red  drug-eluting stent; blue  bare-metal stent.
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Late Clinical Events After DES Versus BMS December 19, 2006:2584–91rug-drug interactions (36) and to treat affected patients
pecifically.
tudy limitations. A major limitation of this study lies in
he fact that power calculations were not based on the
ypothesis of this study. Therefore, the data remain obser-
ational. In view of previous observations (14,15) and a
eta-analysis of 4 randomized sirolimus-eluting stent trials
ith up to 3 years’ follow-up (37), the expected incidence of
ate stent thrombosis was up to 0.3% for BMS and up to
.9% for DES after the first year resulting in an estimated
ample size of 6,000 patients needed to reach statistical
ignificance. Although the present observational data sug-
est a somewhat-greater rate of these events, such a large
tudy of nonselected patients randomized to DES versus
MS will hardly be performed to address this question,
oday.
onclusions. This study highlights the clinical relevance
f a relatively new phenomenon, late clinical events possibly
elated to late stent thrombosis, which seems to be of
articular importance after DES implantation. It could not
rove that thrombosis-related events were significantly
ore frequent after DES compared with BMS; however,
he consistency of the findings within BASKET-LATE
nd with the marked difference in “hard” events, late death
r MI, together with similar directional observations in
revious randomized studies of selected patient groups
nderline the potential relevance of this observation. Al-
hough findings suggest a relation to discontinuation of dual
ntiplatelet therapy, this study gave no proof for a direct
ause-effect relationship nor that thrombosis-related events
ould be prevented by such a therapy. Still, such a strategy
ay be chosen empirically, at least for patients at increased
isk for such events, until better strategies to prevent late
hrombosis-related events have been found and shown to be
ffective. In any case, physicians and patients should be
lerted to this potential late harm of DES use.
eprint requests and correspondence: Dr. Matthias Pfisterer,
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